Guidance document : certificates of supplementary protection.: H164-305/2021E-PDF
"In agreeing to provisionally apply the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada has committed to provide up to two years of sui generis protection for new pharmaceutical products protected by an eligible patent, from the expiry of the patent. Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics and veterinary drugs"--Introduction, page 7.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.894118&sl=0
| Department/Agency | Canada. Health Canada, issuing body. |
|---|---|
| Title | Guidance document : certificates of supplementary protection. |
| Variant title | Certificates of supplementary protection CSP guidance document |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Later edition | Guidance document : |
| Format | Electronic |
| Electronic document | |
| Note(s) | Cover title. Issued also in HTML format. "Effective date: 2021/01/06." Issued also in French under title: Ligne directrice : certificats de protection supplémentaire. |
| Publishing information | Ottawa, ON : Health Canada = Santé Canada, 2021. ©2019 |
| Description | 1 online resource (25 pages) |
| ISBN | 9780660367620 |
| Catalogue number |
|
| Departmental catalogue number | 200313 |
| Subject terms | Patent medicines -- Canada. Patent extensions -- Canada. Pharmaceutical policy -- Canada. |